Factors related to first dose hypotensive effect of captopril: prediction and treatment. 1983

G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson

The blood pressure response to the first dose of captopril (6.25 mg, 12.5 mg, or 25 mg) was measured in 65 treated, severely hypertensive patients. Mean supine blood pressure was 187/108 mm Hg immediately before captopril was given. Twenty one patients experienced a fall in supine systolic pressure greater than 50 mm Hg, including five whose pressure fell more than 100 mm Hg and two whose pressure fell more than 150 mm Hg. Six patients developed symptoms of acute hypotension, including dizziness, stupor, dysphasia, and hemiparesis. Percentage reductions in blood pressure were greatest in those with secondary hypertension (p less than 0.05), high pretreatment blood pressure (p less than 0.05), and high concentrations of plasma renin and angiotensin II (p less than 0.01). No significant correlation was found between fall in blood pressure and serum sodium concentration, age, renal function, and the dose of captopril given. A severe first dose effect cannot be consistently predicted in individual patients who have received other antihypertensive drugs for severe hypertension. Such patients should have close medical supervision for at least three hours after the first dose of captopril.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females

Related Publications

G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
May 1983, British medical journal (Clinical research ed.),
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
April 1983, British medical journal (Clinical research ed.),
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
August 1982, Australian and New Zealand journal of medicine,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
January 1986, Clinical and experimental hypertension. Part A, Theory and practice,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
November 1983, Methods and findings in experimental and clinical pharmacology,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
January 1986, Journal of clinical pharmacology,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
January 1988, Kardiologia polska,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
January 1985, Journal of cardiovascular pharmacology,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
September 1980, European journal of pharmacology,
G P Hodsman, and C G Isles, and G D Murray, and T P Usherwood, and D J Webb, and J I Robertson
December 1990, Postgraduate medical journal,
Copied contents to your clipboard!